Evidence map›Paper›PMID 40476222›Full record

ReviewStem cells and cloning : advances and applications2025

In vitro and In vivo Studies on Mesenchymal Stem Cells for Ischemic Stroke Therapy: A Scoping Review of The Therapeutic Effect.

Ratih Rinendyaputri, Ita Margaretha Nainggolan, Hasta Handayani Idrus, Rachmawati Noverina, Wireni Ayuningtyas, Fathul Huda, Ahmad Faried

Abstract readReview
In one paragraph

Review in Stem cells and cloning : advances and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ratih RinendyaputriCenter for Biomedical Research, Research Organization for Health, National Research and Innovation Agency, Bogor, West Java, Indonesia.ORCID 0000-0002-7527-4079
Ita Margaretha NainggolanEijkman Research Center for Molecular Biology, Research Organization for Health, National Research and Innovation Agency, Bogor, West Java, Indonesia.
Hasta Handayani IdrusCenter for Biomedical Research, Research Organization for Health, National Research and Innovation Agency, Bogor, West Java, Indonesia.
Rachmawati NoverinaBio Farma Stem Cell Research and Development, Bandung, West Java, 40161, Indonesia.
Wireni AyuningtyasBio Farma Stem Cell Research and Development, Bandung, West Java, 40161, Indonesia.
Fathul HudaDepartment of Neurology, Faculty of Medicine, Dr Hasan Sadikin Central General Hospital/Universitas Padjadjaran, Bandung, West Java, 40161, Indonesia.ORCID 0000-0002-4818-1862
Ahmad FariedNeurosurgery Department, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, 40161, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Mesenchymal stem cells (MSCs) have a paracrine impact and may regenerate a variety of tissues. This represents a new prospect in cell-based stroke treatment. Several in vitro and in vivo investigations have demonstrated the neuroprotective and neurogenesis properties of MSCs and their secretome. Purpose: This review provides a comprehensive analysis of the therapeutic effects of MSCs and their secretome on stroke models in vitro and in vivo. Methods: A coverage evaluation is undertaken in accordance with PRISMA-ScR principles. The selection procedure includes the identification of items. Scopus site, PubMed and ScienceDirect, are used for in vitro and in vitro research, including electronic searches. The search terms include "ischemic stroke" or "MCAO", "MSC", "secretome", and "neurogenesis" or "angiogenesis". The searches are limited to English-language articles with full text availability. Results: After selecting 390 papers from two search engines, 94 publications satisfied the review criteria for using MSCs and secretomes for ischemic stroke treatment. We comprehensively review both in vitro and in vivo studies, analyzing aspects such as the source and treatment of MSCs and secretomes, as well as administration, dosage, and mechanisms of therapeutic effects in stroke models. Conclusion: MSC and secretome therapy for stroke have shown promising results in both in vitro and in vivo models. Exploration of alternative MSC sources, refining of isolation techniques, transfection of various proteins, and combination with herbal medicine are all efforts to improve the preclinical model. This work can be used as a reference for preclinical researchers to help with research design and translational research in clinical trials.

Indexed as

conditioned medium/CMmesenchymal stem cells (MSC)middle cerebral artery occlusion (MCAO)secretomestroke ischemic

Identifiers

PMID40476222
PMCPMC12139094

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.